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Abstract
Background: The perioperative period is characterized by an intense inflammatory response. Perioperative 
inflammation promotes postoperative morbidity and increases mortality. Blunting the inflammatory response to 
surgical trauma might thus improve perioperative outcomes. We are studying three interventions that potentially 
modulate perioperative inflammation: corticosteroids, tight glucose control, and light anesthesia.
Methods/Design: The DeLiT Trial is a factorial randomized single-center trial of dexamethasone vs placebo, 
intraoperative tight vs. conventional glucose control, and light vs deep anesthesia in patients undergoing major non-
cardiac surgery. Anesthetic depth will be estimated with Bispectral Index (BIS) monitoring (Aspect medical, Newton, 
MA). The primary outcome is a composite of major postoperative morbidity including myocardial infarction, stroke, 
sepsis, and 30-day mortality. C-reactive protein, a measure of the inflammatory response, will be evaluated as a 
secondary outcome. One-year all-cause mortality as well as post-operative delirium will be additional secondary 
outcomes. We will enroll up to 970 patients which will provide 90% power to detect a 40% reduction in the primary 
outcome, including interim analyses for efficacy and futility at 25%, 50% and 75% enrollment.
Discussion: The DeLiT trial started in February 2007. We expect to reach our second interim analysis point in 2010. This 
large randomized controlled trial will provide a reliable assessment of the effects of corticosteroids, glucose control, 
and depth-of-anesthesia on perioperative inflammation and morbidity from major non-cardiac surgery. The factorial 
design will enable us to simultaneously study the effects of the three interventions in the same population, both 
individually and in different combinations. Such a design is an economically efficient way to study the three 
interventions in one clinical trial vs three.
Trial registration: This trial is registered at Clinicaltrials.gov #: NTC00433251
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Background
Mortality remains substantial among high-risk patients
(ASA physical status 3-5)[1]. In some populations, it is
estimated to be as high as 5-14% during the first postop-
erative year[2-4]. Efforts to identify interventions that
decrease perioperative morbidity and mortality are thus
warranted. The perioperative period is characterized by
a n  i n t e n s e  i n f l a m m a t o r y  r e s p o n s e  m a r k e d  b y  e l e v a t e d
concentrations of inflammatory markers like C-Reactive
Protein (CRP). Inflammation is the body's response to tis-
sue injury[5] and results in production of inflammatory
mediators[6], which are associated with considerable
postoperative morbidity. For example, cardiovascular
mortality is responsible for 17% of post-operative
deaths[3]. Inflammation has been an important mediator
in the pathophysiology of myocardial infarction, at all
stages in the development of vulnerable plaque, from ini-
tial lipid deposition to plaque rupture. Thus, markers of
systemic inflammation such as CRP may better predict
perioperative cardiac morbidity and mortality than cur-
rently utilized strategies[7]. Furthermore, there is an
important link between inflammation and poor perioper-
ative outcomes[7,8]. Thus interventions that moderate
the inflammatory response may prove to reduce adverse
outcomes[9].
Many anti-inflammatory therapies have been tested in
the perioperative period. The anti-inflammatory effects
of corticosteroid are well established[10]. High doses of
methylprednisolone or dexamethasone are important
biologic modifiers of perioperative inflammatory
responses in cardiac surgical patients, and reduce periop-
erative organ dysfunction[11]. Similarly, in non-cardiac
surgery, high-dose steroids reduce the inflammatory
response and improve outcomes[12,13]. Enthusiasm for
use of corticosteroids in cardiac surgery has been damp-
ened by concerns over the potential risks of such large
doses. However, two major reviews concluded that a sin-
gle large dose of corticosteroids appears to be harmless in
the absence of specific contraindications[11,14]. More-
over, Kilger et al. observed a significant reduction in cir-
culating inflammatory marker concentrations, along with
improved outcomes after a small dose of hydrocorti-
sone[15]. And finally, in a randomized trial of patients
undergoing laparoscopic cholecystectomy, 8 mg of dex-
amethasone resulted in significantly lower CRP levels,
significantly reduced postoperative fatigue and postoper-
ative nausea and vomiting (PONV), and a faster return to
recreational activities[16].
Another factor influencing the surgical stress response
and inflammation, and thus postoperative outcomes, is
anesthetic management[17]. For example, deep anesthe-
sia may be associated with adverse outcomes including
mortality. Lennmarken et al. showed that duration at
deep anesthetic levels (BIS < 45) was significantly related
to 1-year mortality, increasing it by 20% per hour,[2] and
that non-survivors spent more time at deep BIS levels
than the survivors[18]. In a cohort of adults having non-
cardiac surgery under general anesthesia, lower BIS levels
were independently associated with higher mortality[3].
In this study, most deaths were attributed to either cancer
or cardiovascular etiologies, the pathogenesis of which
has been well linked to inflammation[19-21]. The authors
postulated that prolonged deep anesthesia increases mor-
tality by aggravating the inflammatory response to sur-
gery[3]. In support of that theory, a pilot study in
orthopedic joint replacement patients demonstrated that
patients who received BIS-guided anesthesia (target 45-
60) showed a reduced post-operative inflammatory CRP
response compared to deeper standard clinical prac-
tice[22].
Hyperglycemia is a physiologic response to surgical
stress and is associated with adverse outcomes[23] such
as impaired wound healing and increased infection risk.
Surgical patients and those suffering acute illnesses often
develop hyperglycemia, even in the absence of a preexist-
ing diabetes[24]. Hyperglycemia is pro-inflammatory and
provokes release of inflammatory cytokines. Fasting
blood glucose concentration is independently related to
CRP levels[25]. On the other hand, insulin per se is anti-
inflammatory and might thus prove beneficial[26,27].
Van den Berghe et al. showed in a prospective random-
ized trial that intensive insulin therapy to maintain blood
glucose at or below 110 mg/dL decreased inflammatory
markers, and significantly reduced overall hospital mor-
tality, blood stream infections, and acute renal failure
among patients in the surgical intensive care unit
(ICU)[28]. Normoglycemia also significantly reduced the
use of catecholamines, and improved long-term rehabili-
tation[29].
The use of normoglycemia or tight glucose control is
not well established in the perioperative period. In a
study in cardiac surgical patients, continuous intravenous
insulin infusion reduced the incidence of deep sternal
wound infection and reduced mortality in diabetic
patients[30,31]. But in another single-center randomized
trial in a similar patient population, tight glycemic con-
trol intraoperatively did not improve outcomes,[32]
although there was a relatively small difference in blood
glucose concentrations in the two groups. Furthermore
all patients received intensive glucose control in the ICU
following their surgery, which may have lessened the
effects of intraoperative glucose control[33].
The effects of intraoperative intensive vs conventional
glucose control on perioperative outcomes in major non-
cardiac surgery remain unknown. Normoglycemia might
decrease postoperative complications such as respiratory,
cardiovascular, renal and neurologic events. One out-
come which has not been studied in the context of tightAbdelmalak et al. BMC Anesthesiology 2010, 10:11
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glucose control is postoperative delirium. Postoperative
delirium is common after certain surgical procedures
with a reported incidence as high as 20-60%[34]. Delir-
ium is an important complication as it significantly
impacts postoperative recovery[35]. The pathogenesis of
delirium remains poorly understood, but there are rea-
sons to believe that inflammation contributes. In vascular
surgery patients, higher preoperative CRP concentrations
augment the probability of postoperative delirium[35]. In
hip fracture surgery, CRP concentrations were signifi-
cantly greater in delirious vs. nondelirious patients [36].
And finally, intraoperative glucose concentrations were
significantly greater in cardiac surgical patients experi-
encing a primary composite outcome that included delir-
ium[23].
Available evidence suggests that blunting the inflam-
matory response to surgical trauma might improve peri-
operative outcomes. The putative benefits from blunting
the surgical stress response are likely to be greatest in
high-risk patients such as those having major non-cardiac
surgery. We are thus studying three interventions poten-
tially modulating perioperative inflammation, corticos-
teroids, tight glucose control and light anesthesia and
their effects on major morbidity and mortality resulting
from major non-cardiac surgery.
Primary hypotheses
major perioperative morbidity in patients having major
non-cardiac surgery is reduced by: 1) low-dose dexame-
thasone; 2) intensive intra-operative glucose control; and
3) lighter anesthesia.
Secondary hypotheses
each intervention reduces circulating concentrations of
the inflammatory marker CRP; CRP concentration corre-
lates with post-operative complications; anesthetic sensi-
tivity predicts major and minor complications, including
delirium. Other secondary hypotheses are that each
intervention reduces minor surgical complications,
reduces PONV, reduces postoperative delirium, speeds
hospital discharge, improves quality of life (SF-12v2
Health Survey, Christensen's VAS fatigue score), and
reduces all-cause one-year mortality.
Methods/Design
Setting and Population
Patients scheduled for elective major non-cardiac surger-
ies at Cleveland Clinic will be evaluated during their pre-
operative anesthesia clinic visits:
Inclusion Criteria
1) Age ≥40 years old;
2) Major non-cardiac surgical procedures;
3) Written informed consent.
Exclusion Criteria
1) Recent intravenous or oral steroid therapy (within 
30 days); inhaled steroids are permitted;
2) Any contraindications to the proposed interven-
tions;
3) ASA Physical Status > 4;
4) Procedures done under regional anesthesia.
Ethics
The study protocol has been reviewed and approved by
the Cleveland Clinic Institutional Review Board (IRB #
07-010)
Study Protocol
Patients will be randomly assigned to each of the follow-
ing interventions:
1) Intravenous Dexamethasone or placebo: 8 mg of 
dexamethasone (or placebo) will be given 1-2 hours 
before incision, 4 mg on the first postoperative morn-
ing, and 2 mg on the second postoperative morning.
2) Intensive or conventional glucose management: 
Patients will be randomized to blood glucose concen-
trations of 80-110 mg.dL-1 (intensive control with a 
specific algorithm) or 180-200 mg.dL-1 (conventional 
control). Glucose control will begin shortly after 
induction of anesthesia using pre-designed protocols 
and continue through the first 2 hours of postanes-
thesia care unit (PACU) stay. Patients will then follow 
the routine of the ICU/hospital ward where they will 
be admitted.
3) Lighter or deeper anesthetic management: 
Patients will be assigned to a target BIS of 55 (lighter 
anesthesia group) or 35 (deeper anesthesia group)
Randomization will be generated by a web-based sys-
tem that will be accessed before anticipated induction of
anesthesia, and will be stratified by history of diabetes.
Patients may be premedicated with intravenous mida-
zolam. Prophylactic antibiotics will be given per surgical
routine. General anesthesia will be induced with fentanyl
and propofol. Tracheal intubation will be facilitated by
succinylcholine or a non-depolarizing muscle relaxant.
Additional non-depolarizing muscle relaxants will be
given as necessary. Anesthesia will be maintained with
sevoflurane in O2 and air combined with a fentanyl infu-
sion; anesthetic drugs will be managed based on the ran-
domized strategy; that is a BIS near 35 or 55. The lungs
will be mechanically ventilated to maintain end-tidal
PCO2 near 35 mmHg. Normothermia will be maintained
with forced-air warming[37]. Blood pressure will be con-
trolled to within a range of +20% to -30% of the preopera-
tive baseline value. Heart rate will be controlled within a
range of 40-90 beats/minute.
Red blood cell transfusions are immunosuppres-
sive[38]. Red cell transfusions will thus be controlled by
protocol. Target minimum hematocrits (HCT) will beAbdelmalak et al. BMC Anesthesiology 2010, 10:11
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determined based on the patient's cardiovascular status.
The HCT will be maintained at 25-28% in patients with-
out substantial cardiac disease, but maintained at 30% in
those with significant cardiac disease, defined as previous
myocardial infarction, angina, congestive heart failure, or
cardiomyopathy.
Measurements
We will record demographic data, ASA physical status,
medical history, drug usage, preoperative hemoglobin
and hematocrit, BUN and creatinine, electrolytes, and
pre-operative electrocardiogram. A BIS sensor will be
applied to the forehead before induction and connected
to a BIS monitor. Anesthetic data will include: the volatile
anesthetic dose in MAC-hours, as well as total doses of
propofol and other sedative hypnotics. Distal esophageal
temperature will be recorded. Blood loss will be esti-
mated; urine output and fluid administration including
allogenic blood will be recorded. Blood pressure and
heart rate will be recorded. Automated intra-operative ST
segment values will be recorded every 15 minutes. BIS
values will be recorded electronically at one-minute
intervals. Perioperative use of antibiotics and intraopera-
tive vasoactive drugs will be recorded.
We will record the admission glucose concentration
and at least hourly glucose concentrations during surgery
and during the first two postoperative hours; the results
of any additional glucose determinations throughout the
hospital stay (obtained for clinical purposes) will also be
recorded. We will use previously described methodolo-
gies to determine efficacy and safety of the insulin infu-
sion protocols, including proportion of time spent within
target range and number of hypoglycemic episodes (< 40
mg.dL-1)[39]. We will also measure time-weighted aver-
age (TWA) glucose and time taken to achieve desired
level of glucose control. We will compare our results to
other published findings in similar trials; the closest to
our trial is that of Gandhi et al who investigated almost
the same targets in their randomized trial in cardiac sur-
gery patients[32]. The time to PACU discharge will be
recorded, along with days in the ICU if applicable, dura-
tion of postoperative mechanical ventilation in hours,
total post-operative opioid use, and the duration of hospi-
talization in days. Blood for high-sensitivity CRP, creati-
nine phospho-kinase and cardiac troponin T
measurements will be sampled at the time of induction, at
post-operative day 1 and 2. A 12-lead electrocardiogram
will be performed immediately post-operatively and the
subsequent morning.
We will use the Confusion Assessment Method (CAM)
as it is the most commonly used tool in the study of delir-
ium. It is easily performed, has a sensitivity of 94% to
100% and a specificity of 90% to 95%[40]. Christensen's
fatigue VAS [41] is one of the most widely used measures
of postoperative fatigue. The test will be administered
pre-operatively and on post-operative days 1 and 3. An
increase of three or more units on the 10- point scale will
be considered a clinically significant increase.
Data Analysis
Our primary outcome is the occurrence of at least one
major complication (Table 1) in a patient within the same
hospitalization and 30-day mortality. Our composite is a
minor modification of the composite outcome used by
Brandstrup et al.[42] and Nisanevich et al.[43]. The use of
a composite adverse outcome indicator rather than inde-
pendently evaluating specific complications likely
reduces the chance of Type 2 error. More importantly,
using any single outcome may not capture the entire
effect of any of our interventions or the complex disease
processes. All analyses will be intention-to-treat.
Primary outcome
Multivariable logistic regression will be used to simulta-
neously assess the effects of the three randomized inter-
ventions, low-dose dexamethasone (vs placebo), intensive
intra-operative glucose control (vs conventional) and
light anesthesia (vs deep), on the primary outcome. We
will first assess the 3-way and 2-way interactions among
the interventions. In absence of interactions, main effects
will be assessed by collapsing over the other interven-
tions. Otherwise, the main effects will be assessed within
levels of the interacting factors.
CRP
A linear mixed effects model (random subject, fixed
interventions and time) will be used to assess the effects
of the three interventions on CRP at the 1st and 2nd post-
operative days, adjusting for baseline. In addition, the
association between CRP (each time, plus change from
baseline) and outcomes of interest will be assessed using
logistic regression, adjusting for intervention.
All-cause mortality
Multivariable Cox proportional hazard survival models
will be used to assess the relationship between the inter-
ventions and all-cause mortality, comparing groups on
overall and 12-month survival.
Additional outcomes
Time-to-event outcomes (e.g., time to death, hospital
LOS, and ICU LOS) will be analyzed using Cox regres-
sion, while binary outcomes (e.g., minor perioperative
complication composite (Table 2), delirium, and PONV)
will be analyzed using logistic regression, and continuous
variables (including SF-12) using linear regression or a
non-parametric alternative. Additional analyses will be
performed adjusting for any baseline potentially con-
founding factors for which clinical imbalance between
randomized groups is observed. The significance level
will be 0.05 for all main effect hypotheses, and 0.10 for
interactions. Table 3 summarizes the timing of interven-
tions and outcomes' measures.Abdelmalak et al. BMC Anesthesiology 2010, 10:11
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Interim Monitoring Plan and Adaptive Design Options
The first stage of the study will be a traditional (i.e., non-
adaptive) group sequential design[44,45], where interim
analyses for both efficacy and futility will be conducted
after 25%, 50% and 75% of the patients have been
enrolled, and at the end of planned enrollment, as
needed. Interventions with either a large or very small
treatment effect will likely cross boundaries for efficacy
or futility, respectively, at one of the interim analyses, and
be stopped early. By the final analysis (including a possi-
ble adaptive stage, as explained below), all of the inter-
ventions will have either crossed an efficacy or futility
boundary.
Interim Monitoring Details
We will use the gamma spending function[46] to monitor
efficacy (gamma = -3, similar to O'Brien-Fleming) and
futility (gamma = 0, similar to Pocock), spending Type I
error, which monitors efficacy, slower than the Type II
error, which monitors futility, in order to facilitate early
stopping for either, but more so for futility (Figure 1). P-
values for crossing efficacy (futility) boundaries for the
1st, 2nd, 3rd and final analyses will be ≤ 0.003 (> 0.972), ≤
0.007 (> 0.936), ≤ 0.017 (> 0.526) and ≤ 0.041 (> 0.041),
respectively, for the 3 interim looks and final analysis of
the initial group sequential stage (Figure 2). The overall
significance level of 0.05 and power of 0.90 will be main-
tained. Interim results, along with a recommendation on
whether to continue any or all interventions, will be given
to the study's Executive Committee which will determine
whether to halt or continue the trial at each juncture.
Adaptive Design Option
At the third planned group sequential analysis (N = 728
patients), an adaptive sample size extension of the trial
may be proposed to study one or more of the interven-
tions that showed a modest but important treatment
effect but had not yet crossed an efficacy (or futility)
boundary. The method of Muller and Schafer[47] would
be used to the extent that intervention with an increased
sample size in a second stage while preserving the overall
Type I error of the study. A second stage with new stop-
Table 1: Components of the composite primary outcome
Major Complications Requirements for acceptance
Deep or organ/space surgical site infection CDC criteria[49]
Sepsis Positive blood culture and at least two of the following: Hypo or hyperthermia, tachycardia, 
tachypnea, leucopenia/leukocytosis ± DIC or multiorgan dysfunction
Bowel and surgical anastomosis stricture/
obstruction or anastomotic leak
Requiring surgical intervention
Vascular graft thrombosis Requiring surgical intervention
Bleeding Requiring transfusion > 4 units of RBCs within the first 72 hours after surgery
Large peritoneal/pleural effusion Diagnosed by X-Ray, ultrasound, and/or aspiration, and requiring chest tube, surgery, or 
ICU admission
Internal or external fistula formation Requiring intervention
Stroke New focal neurologic deficit of presumed vascular etiology persisted more than 24 hr with 
a neurologic study that did not indicate a different etiology
Pulmonary emboli (PE) Sudden death or confirmation by V-Q scan showing high probability for PE, spiral CT scan 
or pulmonary arteriogram
Pulmonary edema and congestive heart failure Shortness of breath, crepitation, peripheral edema and third heart sound and radiologic 
signs (cardiomegaly, interstitial edema, alveolar edema), medical treatment with diuretics
Myocardial infarction ECG changes and/or elevated myocardial enzymes (cTn-T ≥0.2 ng/mL and/or CK ≥170IU 
and MB ≥5%)
Ventricular arrhythmias ECG changes requiring medical treatment and/or electro-conversion
Renal failure Requiring dialysis
Mortality All-cause death within 30 postoperative days
Respiratory failure Requiring intubation for more than 3 days
Pneumonia New infiltrate on CXR combined with 2 of the following: temperature > 38°C, leukocytosis, 
and positive sputum or bronchial culture
CDC = Center for Disease Control; DIC = Disseminated Intravascular Coagulopathy; ICU = Intensive Care Unit; VQ = Ventilation Perfusion; CT = 
Computed Tomography; ECG = Electrocardiogram; CXR = Chest X-RayAbdelmalak et al. BMC Anesthesiology 2010, 10:11
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ping boundaries would be designed with sample size and
planned interim analyses to be able to detect a revised
treatment effect with the desired power. Results from the
1st and 2nd stages for that intervention would be combined
in a final analysis. East and SAS statistical software will be
used for the sample size calculations, interim analyses
and final analyses.
Sample size considerations
We estimate that 25% of patients receiving no interven-
tion (i.e., the control) will have at least one major compli-
cation. We further hypothesize that all interventions will
not have the same effect and will power the study for a
relative reduction of 40% or more for at least one inter-
vention, and 20% and 10% versus respective controls for
the other two. Our design will thus require a maximum of
970 total patients for the original group sequential por-
tion of the study to have 90% power at the 0.05 signifi-
cance level to detect a 40% reduction on the primary
outcome for the most promising intervention.
Discussion
A factorial design will enable us to simultaneously study
the effects of the three interventions; dexamethasone vs
placebo, intraoperative tight vs. conventional glucose
control, and light vs deep anesthesia, in the same popula-
tion, both individually and in different combinations.
Such a design is an economically efficient way to study
the three interventions in one clinical trial vs three, espe-
cially if there is no statistical interaction between the
treatments[48].
In fact, we do not expect an interaction between the
three interventions; that is, the effect of one intervention
should not depend on the presence or absence of the
other. But in the event that the efficacy of one interven-
tion does depend on another (e.g., steroids improve out-
comes only if glucose is controlled), a factorial design will
enable us to quantify the magnitude of the interaction. In
contrast, this sort of interaction would be impossible to
observe with three separate univariate trials. Factorial
design is thus not only more efficient, but often superior
to conventional trials that evaluate only a single interven-
tion.
In our case, all three interventions are presumed to
exert their protective effects through the same mecha-
nism -- modulation of the peri-operative inflammatory
response -- albeit possibly via different pathways. How-
ever, the putative effects of each are limited by a ceiling
effect. Thus, a strength of the proposed factorial design is
that we will be able to evaluate the presumed additive
benefits of each intervention.
An added strength to our trial is that we will evaluate
"hard" outcomes (major complications and mortality)
rather than intermediate or indicator outcomes. Further-
more, the interventions we will test are fairly easy to use,
inexpensive, and low-risk.
Limitations
The dose of steroids we have chosen may prove sub-opti-
mal. Large-dose steroids have been shown to improve
perioperative outcomes in patients undergoing cardiac or
colorectal surgery[11,14]. However, concerns were raised
Table 2: Minor Complications
Complication Requirements for acceptance
Superficial incisional surgical site infection, or hematoma Surgical evacuation of hematoma and or CDC
Intra-operative ST segment ischemia An ischemic episode is defined as an ST segment change showing either ≥ 1 
mm depression or ≥ 1.5 mm elevation from baseline
Unplanned ICU admission Unplanned ICU admission
Minor surgical intervention Surgeon called for care issues during the first 2 hours postoperatively
Non-ventricular arrhythmias ECG changes, medical Rx and/or electroconversion
Small peritoneal/pleural effusion Diagnosed by X-Ray, ultrasound, and/or aspiration, and not requiring chest 
tube, surgery, or ICU admission
Ileus Lasting more than 72 hours
DVT Diagnosed by Doppler examination, venogram, or CT scan
Cystitis or urinary tract infection Fever, dysuria and positive urine culture
Hemodynamic disturbances Requiring vasoactive drugs and/or β blocker treatment in the first 2 hours 
postoperatively
Progressive renal insufficiency Rise in creatinine of > 2 mg/dl from pre-operative value but with no 
requirement for dialysis
CDC = Center for Disease Control; ICU = Intensive Care Unit; DVT = Deep Venous Thrombosis; Rx = treatment; ECG = Electrocardiogram; CT = 
Computed TomographyA
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Table 3: Flow -chart of timing of the interventions and outcomes measures
Pre-op 
visit
Preop 
Immediate
Intra-op Post-op 
immediately
POD1 POD2 POD3 Hospitalization 30-day 6, 12 months
Dexamethasone 
(8 mg)
Dexamethasone 
(4 mg)
Dexamethason
e (2 mg)
Interventions Depth of 
Anesthesia
Glucose 
Control
Glucose Control
Composite 
Primary 
outcome
Primary 
outcome 
(mortality)
Secondary 
outcomes
Secondary 
outcomes
Secondary 
outcomes
SF-12 SF-12
Outcomes Christensen 
Fatigue 
Score
Christensen 
Fatigue Score
Christensen 
Fatigue Score
CAM ICU - twice 
daily
CAM ICU - twice 
daily
CAM ICU - twice 
daily
Phone call- vital 
status
Phone call- vital 
status
EKG EKG EKG
Cardiac Enzymes 3 × 8 hrs apart
CRP CRP CRP
POD = post operative day; SF 12 = health-related quality of life measure; CRP = C-Reactive Protein; CAM ICU =Confusion Assessment Method-ICUAbdelmalak et al. BMC Anesthesiology 2010, 10:11
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about the possibility of theoretical side effects of such a
large dose. Subsequent work by Kilger and associates sug-
gests that much smaller doses are also effective,[15] and
are -- presumably -- considerably safer. The anti-inflam-
matory potency of the dose we have chosen is compara-
ble to that used by Kilger, although, we used
dexamethasone rather than hydrocortisone[49]. It is also
in line with the study by Bisgaard et al. that resulted in
significantly lower CRP levels and improved recovery
parameters. There was no increase in wound infection or
other adverse outcomes[16]. Steroid administration will
start 1-2 hours before surgery because the effects of ste-
roids are believed to be mediated by protein synthesis
which usually takes an hour or two[50].
Patients will be randomized to either a tight glucose
control group with a goal of 80-110 mg·dl-1 or to a con-
ventional care group with a goal of 180-200 mg·dl-1. The
lower range is that used by Van den Berghe et al, [28] and
was shown to be beneficial in critical care patients. There
were few complications associated with tight control in
such a low range. The higher range essentially corre-
sponds to current routine clinical practice. For example, a
recent retrospective study showed that the rates of insulin
treatment among academic anesthesiologists for glucose
values < 140 mg·dl-1, 140-200 mg·dl-1, or > 200 mg·dl-1
were 0.1%, 1.4%, and 11.9%, confirming that many anes-
thesiologists do not treat intraoperative glucose values
less than 200 mg·dl-1[51].
Clinicians and study coordinators will be blinded to
dexamethasone treatment. But due to the nature of the
interventions, clinicians will not be blinded to the ran-
domization regarding level of glucose control and depth
of anesthesia in any given patient. The data collectors for
postoperative events will be blinded to all three interven-
tions.
Conclusion
The DeLiT Trial is a multi-factorial randomized single-
center trial of dexamethasone vs placebo, intraoperative
tight vs. conventional glucose control, and light vs deep
anesthesia in patients undergoing major non-cardiac sur-
gery. The primary outcome is a composite of major post-
operative morbidity including myocardial infarction,
stroke, sepsis, and 30-day mortality. C-Reactive protein, a
measure of the inflammatory response, will be evaluated
as a secondary outcome. One-year all-cause mortality as
well as post-operative delirium will be additional second-
ary outcomes. We will enroll up to 970 patients which
will provide 90% power to detect a 40% reduction for the
primary outcome, including three equally spaced interim
analyses for efficacy and futility.
Figure 1 Spending functions for alpha or type I error (on left ver-
tical axis) and beta or type II error (on right vertical axis) as a func-
tion of information time on horizontal axis, where information 
time is the proportion of the maximum planned sample size 
available for a particular interim analysis. Lines represent the cu-
mulative error spent throughout the trial. Beta is spent faster than al-
pha to allow the study to stop early more readily for futility than for 
efficacy. Lines are continuous, allowing flexibility in choice of monitor-
ing times, but interim monitoring will only be done at the pre-specified 
times for this study.
Figure 2 Stopping boundaries for efficacy and futility. Plot of the 
standardized treatment effect (z- statistic) on vertical axis and ac-
crued sample size on the horizontal axis, where a z-statistic of 
zero indicates no treatment effect. Outside shaded regions indicate 
sufficient evidence to reject null hypothesis for efficacy (top) or harm 
(below), while inside shaded region indicates evidence to stop for fu-
tility, or no effect.Abdelmalak et al. BMC Anesthesiology 2010, 10:11
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